---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-278835"
form_type: "8-K"
ticker: "XLO"
cik: "0001840233"
company_name: "Xilio Therapeutics, Inc."
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:32:55.583337+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Xilio Q3 net loss $16.3M; cash $103.8M; vilastobart 40% ORR in MSS mCRC subset

## Summary
- Net loss $16.3M for Q3 2025 vs $14.0M in Q3 2024; collaboration revenue $19.1M (up from $2.3M YoY).
- Cash $103.8M at Sep 30, 2025; plus $17.5M milestone from Gilead in Q4; runway into Q1 2027.
- Vilastobart Phase 2 data: 40% ORR in heavily pretreated MSS mCRC without liver metastases and high plasma TMB (≥10 mut/Mb).
- Efarindodekin alfa Phase 1 data showed monotherapy activity; RP2D selected; $17.5M milestone from Gilead achieved.
- XTX501 IND planned mid-2026; masked T cell engagers advancing with PSMA, CLDN18.2, STEAP1 candidates.

## SEC filing metadata
- accession: 0001193125-25-278835
- form_type: 8-K
- ticker: XLO
- cik: 0001840233
- company_name: Xilio Therapeutics, Inc.
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840233/000119312525278835/0001193125-25-278835-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840233/000119312525278835/xlo-20251112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-278835
- JSON: https://secwatch.observer/filing/0001193125-25-278835.json
- Plain text: https://secwatch.observer/filing/0001193125-25-278835.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.